Plandai Biotechnology, Inc. Petitions South Africa Department of Health for License to Conduct Cannabis Research
April 28 2014 - 8:50AM
Marketwired
Plandai Biotechnology, Inc. Petitions South Africa Department of
Health for License to Conduct Cannabis Research
License Sought to Explore Therapeutic and Medical Benefits of
Marijuana
SEATTLE, WA--(Marketwired - Apr 28, 2014) - Plandaí
Biotechnology, Inc. (OTCQB: PLPL), a producer of highly
bioavailable plant extracts for industries including health,
wellness, nutraceutical, and pharmaceutical, today announced it has
filed a petition with the Attorney General from the South African
Department of Health to obtain a license permitting the company to
commence clinical research on the therapeutic and medicinal
benefits of cannabis. The petition was made pursuant to Section 22A
(9) of the Medicines and Related Substances Act No. 101 of 1965,
which provides for pharmaceutical research with cannabis.
Apart from the well-known medical benefits of cannabis, such as
reducing nausea, improving appetite and reducing anxiety,
cannabinoids have shown promise in multiple studies for treating
various cancers, epilepsy, pain relief, and in neurological
diseases including Alzheimer's, Parkinson's, dementia and Multiple
Sclerosis. Legal limitations, however, have prevented researchers
from conducting thorough double-blind clinical trials on these and
other potential medical applications of cannabis. By obtaining a
research license in South Africa, Plandaí hopes to test its
Phytofare Cannabinoid Extract at several qualified university
research facilities with the goal of eventually obtaining solid
human clinical data and government drug acceptance in the U.S. and
elsewhere.
Jamen Shively, Vice President of Marketing for Plandaí,
commented, "As a society, we have relied far too long on anecdotal
evidence and the few limited trials that have taken place involving
medical marijuana. Plandaí is committed to bringing cannabis
research to the forefront as a potential treatment or cure for
various diseases and conditions. We believe solid research,
conducted under full legal authority by top independent facilities,
is the key to ending prohibition and allowing patients to benefit
from the medical benefits of marijuana without feeling like
criminals or addicts."
Plandaí's live-plant extraction process recovers phytonutrients
from plant material in a mainly nano particle form and rearranges
the antioxidants (polyenes) into a format bio-compatible with
humans and animals. In addition, through Plandaí's agreement with
North West University, South Africa, the company holds the world
license to the Pheroid® patented entrapment system to deliver
protected Phytofare™ antioxidants to the white blood cells. The
result of these two combined technologies is the ability to finally
deliver a clinical, pharmaceutical-grade dose of non-psychoactive
cannabinoids to human tissues, thereby unlocking the promise of
using natural products to fight many of mankind's most elusive and
deadly diseases.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly
bioavailable, phytonutrient rich extracts which are being utilized
to deliver a new family of drugs to safely and affordably treat a
multitude of diseases and conditions. Plandaí Biotechnology
controls every aspect of the process, from growing the raw
materials on its farms in South Africa, to producing its patented
Phytofare™ extracts in-house, allowing the Company to guarantee the
continuity of supply as well as quality control throughout the
entire process. Targeted industries for the Company's products
include beverage, cosmeceutical, wellness, nutraceutical,
anti-aging, and pharmaceutical. For more information, please visit
http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements
and involve risks and uncertainties. Results, events and
performances could vary from those contemplated. These statements
involve risks and uncertainties which may cause actual results,
expressed or implied, to differ from predicted outcomes. Risks and
uncertainties include product demand, market competition, and
Plandaí's ability to meet current or future plans. Investors should
study and understand all risks before making an investment
decision. Readers are recommended not to place undue reliance on
forward-looking statements or information. Plandaí is not obliged
to publicly release revisions to any forward-looking statement, to
reflect events or circumstances afterward, or to disclose
unanticipated occurrences, except as required under applicable
laws.
Contact: Andrew Beyer Phone: 888-627-6902 Email:
investor@Plandaíbiotech.com
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Apr 2023 to Apr 2024